New cholesterol drug tested in taiwan: hope for Statin-Intolerant patients
NCT ID NCT06925100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested bempedoic acid, a new cholesterol-lowering drug, in 180 Taiwanese adults with high cholesterol or mixed lipid problems. Participants took a 180 mg tablet daily for 12 weeks. The goal was to see how much it lowered 'bad' LDL cholesterol and whether it was safe, especially for those who cannot take statins. Results could help doctors manage cholesterol more effectively in this population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bempedoic acid
- What this could lead to
- If successful, this could confirm that bempedoic acid works well and safely for lowering cholesterol in Taiwanese patients, offering a new option for those who cannot take statins.
- What could go wrong
- This is a small, short-term study (12 weeks) with no comparison group, so results may not prove long-term benefits or apply to all patients. Side effects are possible, though muscle problems are less likely than with statins.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
180 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. At least 18 years of age 2. Diagnosed with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia: * Patients who have been on statin or statin combining with other lipid-lowering therapies\* (both under the maximum tolerated dose of statin) for at least 4 weeks, but unable to reach LDL-C goals† OR * Patients who are statin-intolerant or contraindicated to statin, alone or have been on other non-statin lipid-lowering therapies\* for at least 4 weeks, but unable to reach LDL-C goals† \* Other lipid-lowering therapies: Ezetimibe, Cholesterol and/or bile acid, absorption inhibitors, PCSK9 inhibitors, Omega-3 fatty acids, Fibrates, or Niacin derivatives † LDL-C goals are defined as: * Patients with ASCVD or had conducted coronary revascularization procedures (e.g., PCI or CABG): LDL-C \< 70 mg/dL * Patients aside from the above population: LDL-C \< 100 mg/dL 3. The physician intends to prescribe bempedoic acid per locally approved label (the study intends no intervention in physicians' judgement on the prescription of bempedoic acid) 4. Provide written informed consent Exclusion Criteria: 1. Concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is acceptable) 2. With eGFR \< 30 mL/min/1.73 m2, end-stage renal disease (ESRD) on dialysis, severe hepatic impairment (Child-Pugh C), bempedoic acid contraindications (i.e., hypersensitivity to the active substance or any of the excipients, galactose intolerance, pregnancy, breastfeeding, concomitant use with simvastatin \> 40 mg daily)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary hypercholesterolemia or mixed hyperlipidemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Far Eastern Memorial Hospital
New Taipei City, 220, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
-
Linkou Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.